{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:47:36Z","timestamp":1792450056218,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>The separation of sarcomatous and desmoplastic mesotheliomas from benign organizing pleuritis can be morphologically very difficult. Deletion of p16 (<jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>) by fluorescence in situ hybridization (FISH) testing appears to be a reliable marker of malignancy in mesothelial proliferations, and more recently it has been reported that, in this setting, loss of BAP1 by immunohistochemistry is only seen in malignant mesotheliomas. To determine how useful these tests are with sarcomatous and desmoplastic mesotheliomas, we examined 20 such tumors. Loss of BAP1 was seen in 3\/20 (15%) and deletion of p16 by FISH was seen in 16\/20 (80%) cases. Loss of one or the other marker was observed in 17\/20 (85%). We also examined 13 sarcomatoid carcinomas, an important differential diagnosis of sarcomatoid mesotheliomas, and found that BAP1 was never lost, but p16 was deleted in 3\/11 (27%). We conclude that: (1) BAP1 immunohistochemistry is relatively insensitive in the context of sarcomatous and desmoplastic mesotheliomas, but as a matter of time and cost efficiency may nonetheless be a useful first approach to the problem; (2) deletion of p16 by FISH is considerably more sensitive, but there remain a proportion of cases in which p16 is not deleted; (3) a small improvement in sensitivity can be achieved by using both markers; (4) in the context of a spindle cell malignant tumor in the pleura or peritoneum, which morphologically might be a metastatic sarcomatoid carcinoma or a mesothelioma, the finding of BAP1 loss favors mesothelioma, but p16 FISH cannot be used to separate sarcomatous mesotheliomas from sarcomatoid carcinomas.<\/jats:p>","DOI":"10.1097\/pas.0000000000000616","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T14:02:24Z","timestamp":1455976944000},"page":"714-718","source":"Crossref","is-referenced-by-count":94,"title":["BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas"],"prefix":"10.1097","volume":"40","author":[{"given":"Harry C.","family":"Hwang","sequence":"first","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Pyott","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlie","family":"Cindric","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Carr","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Thompson","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Tse","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen M.","family":"Gown","sequence":"additional","affiliation":[{"name":"PhenoPath Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/00000478-200009000-00001","article-title":"The separation of benign and malignant mesothelial proliferations","volume":"24","author":"Churg","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5858\/arpa.2012-0112-RA","article-title":"The separation of benign and malignant mesothelial proliferations","volume":"136","author":"Churg","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jclinpath-2012-201303","article-title":"Challenges and controversies in the diagnosis of mesothelioma: Part 1.Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson","year":"2013","journal-title":"J Clin Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","article-title":"Tumours associated with BAP1 mutations","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"e35295","DOI":"10.1371\/journal.pone.0035295","article-title":"Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families","volume":"7","author":"Njauw","year":"2012","journal-title":"PLoS One"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"suppl 1","key":"R12-20230922","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1827.2010.02534.x","article-title":"9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis","volume":"60","author":"Takeda","year":"2010","journal-title":"Pathol Int"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5858\/arpa.2012-0108-OA","article-title":"p16 Deletion in sarcomatoid tumors of the lung and pleura","volume":"137","author":"Tochigi","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/modpathol.2009.180","article-title":"Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases","volume":"23","author":"Klebe","year":"2010","journal-title":"Mod Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201605000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:23:00Z","timestamp":1695421380000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201605000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000616","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}